Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO 3 fusions
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
In colorectal cancer (CRC), WNT pathway activation by genetic rearrangements of RSPO3 is emerging as a promising target.However, its low prevalence severely limits availability of preclinical models for in-depth characterization.Using a pipeline designed to suppress stroma-derived signal, we find that RSPO3 "outlier" expression in CRC samples highlights translocation and fusion transcript expression.Outlier search in 151 CRC cell lines identified VACO6 and SNU1411 cells as carriers of, respectively, a canonical PTPRK(e1)-RSPO3(e2) fusion and a novel PTPRK(e13)-RSPO3(e2) fusion.Both lines displayed marked in vitro and in vivo sensitivity to WNT blockade by the porcupine inhibitor LGK974, associated with transcriptional and morphological evidence of WNT pathway suppression.Long-term treatment of VACO6 cells with LGK974 led to the emergence of a resistant population carrying two frameshift deletions of the WNT pathway inhibitor AXIN1, with consequent protein loss.Suppression of AXIN1 in parental VACO6 cells by RNA interference conferred marked resistance to LGK974.These results provide the first mechanism of secondary resistance to WNT pathway inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Moreover, as previously observed for the EGFR pathway (De Roock et al , 2010; Misale et al , 2014), both primary and secondary resistance to blockade of a central switch in a key signaling pathway can be achieved by genetic alterations affecting downstream nodes of the same pathway.”
Self-citationMarisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Sequential cancer mutations in cultured human intestinal stem cells
Drost, J., van Jaarsveld, R. H., Ponsioen, B., Zimberlin, C., van Boxtel, R., Buijs, A., Sachs, N., Overmeer, R. M., Offerhaus, G. J., Begthel, H., et al. (2015) · Nature · doi:10.1038/nature14415 · Cited by 1,067
Recurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960 · cited 3×
“Identification of RSPO 3 rearrangements in CRC samples by combined stroma/transcript expression analysis PTPRK-RSPO3 rearrangements typically lead to aberrant expression of fusion transcripts by colorectal cancer cells that normally do not express RSPO3 (Sato et al , 2009; Seshagiri et al , 2012).”
Intratumor Heterogeneity: Evolution through Space and Time
Swanton, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2217 · Cited by 931 · cited 2×
“APC alterations typically occur at early steps of the colorectal adenoma–carcinoma sequence (Powell et al, 1992; Morin et al, 1997), a typical feature of “trunk” genetic events, present in all cancer cells and therefore therapeutically attractive (Swanton, 2012).”
The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength
de Lau, W., Peng, W. C., Gros, P., & Clevers, H. (2014) · Genes & Development · doi:10.1101/gad.235473.113 · Cited by 656
Stromal contribution to the colorectal cancer transcriptome
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3224 · Cited by 640 · cited 15×
“…RSPO3 transcript expression in CRC samples, we exploited our previously assembled 450-sample TCGA mRNA dataset, available as Experiment Data package from Bioconductor: http://www.bioconductor.org/packages/release/data/experiment/ html/TCGAcrcmRNA.html, as described elsewhere (Isella et al , 2015).”
InfluentialSelf-citationdeFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data
McPherson, A., Hormozdiari, F., Zayed, A., Giuliany, R., Ha, G., Sun, M. G. F., Griffith, M., Heravi Moussavi, A., Senz, J., Melnyk, N., et al. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001138 · Cited by 557 · cited 2×
“Bioinformatic analyses to define the presence of fusion transcripts in TCGA RNA-seq data were accomplished using Defuse (McPherson et al , 2011) and ChimeraScan (Iyer et al , 2011) for paired-end samples, while Mapsplice (http://www.netlab.uky.edu/p/bioinfo/ MapSplice2) was used for single-end…”
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · cited 2×
“As for all pathway-targeted therapies, availability of experimental models is crucial to characterize the dependency on pathway activators and to explore possible mechanisms of release from such dependency (Misale et al , 2014; Rosa et al , 2014).”
Self-citationThe landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015) · Oncogene · doi:10.1038/onc.2014.406 · Cited by 450 · cited 1×
“Cross-check with an available pan-cancer database of fusion transcripts in TCGA samples (http://www.tumorfusions.org; Yoshihara et al , 2015) revealed that no additional RSPO3 fusions were detected in the 450-sample TCGA dataset used for our analysis.”
Cited by
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
“This kind of drug resistance is accomplished by LoF of Axin1 in the VACO6.”
Mutations and mechanisms of WNT pathway tumour suppressors in cancer
Bugter, J. M., Fenderico, N., & Maurice, M. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00307-z · Cited by 466
WNT as a Driver and Dependency in Cancer
Parsons, M. J., Tammela, T., & Dow, L. E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0190 · Cited by 257
Herpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00359-0 · Cited by 178
Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
Prossomariti, A., Piazzi, G., Alquati, C., & Ricciardiello, L. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.04.007 · Cited by 155
Metadata
- Authors
- Picco, G., Petti, C., Centonze, A., Torchiaro, E., Crisafulli, G., Novara, L., Acquaviva, A., Bardelli, A., & Medico, E.
- Venue
- EMBO Molecular Medicine
- Published
- 2017-01-18
- Volume
- 9
- Issue
- 3
- Pages
- 293-303
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2578928713
- Cited by
- 64
- References
- 12
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO 3 fusions. https://app.cochat.ai/papers/10.15252/emmm.201606773
- The paper
- Picco, G., Petti, C., Centonze, A., Torchiaro, E., Crisafulli, G., Novara, L., Acquaviva, A., Bardelli, A., & Medico, E. (2017). Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO 3 fusions. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201606773
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.